is tirzepatide bad for kidneys (Zepbound) showed improved kidney function in obese patients with both chronic kidney disease and #heartfailure with preserved ejection fraction, highlighting its potential to address this high-risk patient population. Read more: https Medications for Type 2 Diabetes

Eli Lilly released phase 3 results from late-stage trials in 2025 and 2026, covering patients with Type 2 diabetes and obesity

Understanding where the regulations are heading helps you anticipate disruptions and adjust your sourcing strategy before you are forced to by another vendor shutdown

10.1196/annals.1320.012

and is the residual error

The reported E-value of 3.31 suggests that an unmeasured confounder would need relatively strong associations with both semaglutide use and COVID-19-related mortality to fully explain the finding, but it does not eliminate that possibility

This extra energy could lead you to be more active, which in turn could help with your weight loss goals [14]